We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

134 hedge funds and large institutions have $346M invested in 4D Molecular Therapeutics in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 31 increasing their positions, 48 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

487% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $191K

129% more capital invested

Capital invested by funds: $151M → $346M (+$195M)

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

12% more funds holding

Funds holding: 120 → 134 (+14)

2.52% less ownership

Funds ownership: 87.21% → 84.68% (-2.5%)

35% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 48

Holders
134
Holders Change
+14
Holders Change %
+11.67%
% of All Funds
1.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
31
Reduced
48
Closed
19
Calls
$1.12M
Puts
$191K
Net Calls
+$930K
Net Calls Change
+$906K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$4.76M
2
Deutsche Bank
Deutsche Bank
Germany
+$1.89M
3
PHP
Parkman Healthcare Partners
Connecticut
+$1.2M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.18M
5
SSA
Schonfeld Strategic Advisors
New York
+$1.07M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.24M
2
Millennium Management
Millennium Management
New York
-$2M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.65M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.54M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHP
26
Parkman Healthcare Partners
Connecticut
$1.74M +$1.2M +200,000 New
PFM
27
Privium Fund Management
Netherlands
$1.72M – – –
SSA
28
Schonfeld Strategic Advisors
New York
$1.56M +$1.07M +179,075 New
Adage Capital Partners
29
Adage Capital Partners
Massachusetts
$1.52M +$1.05M +175,000 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1.5M -$3.69K -618 -0.4%
SWGC
31
Summit Wealth Group (Colorado)
Colorado
$1.47M +$78.9K +13,204 New
PWM
32
Perigon Wealth Management
California
$1.27M – – –
Marshall Wace
33
Marshall Wace
United Kingdom
$1.27M -$668K -111,713 -43%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.23M +$3.68K +616 +0.4%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$1.18M +$810K +135,470 New
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$1.16M – – –
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$1.15M +$47.9K +8,013 +6%
Invesco
38
Invesco
Georgia
$1.1M -$82.2K -13,746 -10%
Jane Street
39
Jane Street
New York
$1.02M -$439K -73,458 -39%
UBS Group
40
UBS Group
Switzerland
$825K -$9.68K -1,619 -2%
N
41
Nuveen
North Carolina
$816K -$40.6K -6,786 -7%
Barclays
42
Barclays
United Kingdom
$815K -$107K -17,951 -16%
DC
43
Decheng Capital
California
$806K -$877K -146,762 -61%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$779K +$154K +25,710 +40%
TI
45
Trexquant Investment
Connecticut
$707K +$486K +81,354 New
American Century Companies
46
American Century Companies
Missouri
$605K +$124K +20,809 +43%
Fidelity Investments
47
Fidelity Investments
Massachusetts
$570K +$20.9K +3,504 +6%
AllianceBernstein
48
AllianceBernstein
Tennessee
$567K – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$558K -$10.6K -1,779 -3%
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$504K +$12.4K +2,069 +4%
1
2
3 4 5

FDMT Hedge Fund Activity: Q3 2025 in Review

134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2025, worth a combined $346M — up 129% from $151M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new FDMT positions and 19 closed out — a net gain of 14 holders — while 31 added to existing stakes and 48 trimmed.

The largest buyer was Armistice Capital, adding an estimated $4.76M. The largest seller was JP Morgan Chase, cutting an estimated $2.24M.

  • 134 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2025, up from 120 in Q2 2025.
  • Funds reported $346M of 4D Molecular Therapeutics stock for Q3 2025, up 129% quarter-over-quarter.
  • 33 funds opened new 4D Molecular Therapeutics positions in Q3 2025 and 19 closed out, a net change of +14 holders.
  • The largest 4D Molecular Therapeutics buyer in Q3 2025 was Armistice Capital, an estimated $4.76M added.
  • The largest 4D Molecular Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $2.24M sold.

Based on aggregated 13F filings for Q3 2025.